New developments in the treatment of hepatitis C

Rossi, S.J.; Wright, T.L.
May 2003
Gut;May2003, Vol. 52 Issue 5, p756
Academic Journal
Reports on developments in the treatment of hepatitis C. Factors that hinder the development of effective antiviral agents for the disease; Features of the process of pegylation; Comparators used in the clinical trials of peginterferon in combination with ribavirin.


Related Articles

  • Peginterferon/ribavirin/telaprevir.  // Reactions Weekly;1/11/2014, Issue 1483, p80 

    The article presents a case report on the adverse effects of peginterferon, ribavirin, and telaprevir to 12 patients who experienced toxicities after receiving the treatment for their hepatitis C.

  • Duration and Dose of Antiviral Treatment for Chronic Hepatitis C.  // Annals of Internal Medicine;3/2/2004, Vol. 140 Issue 5, pI67 

    Reports on the duration and dose of antiviral treatment for Chronic Hepatitis C. Effective combination of a long-acting immunity-boosting protein with another antiviral drug in ridding the body of HCV; Requirement of higher ribavirin doses by the patients with chronic hepatitis and HCV genotype 1.

  • Anti-Viral Therapies for Hepatitis C Virus Infection: Current Options and Evolving Candidate Drugs. Fanning, Liam J. // Letters in Drug Design & Discovery;Mar2005, Vol. 2 Issue 2, p150 

    Chronic hepatitis C is a ubiquitous disease, affecting approximately 170 million globally. The hepatitis C virus (HCV) is spread by parenteral transmission of body fluids, primarily blood or blood products. The hepatitis C viral genome is a positive-sense, single-stranded RNA molecule...

  • Therapy of Acute Hepatitis C: A Review of Literature. Santantonio, T.; Fasano, M. // Current Pharmaceutical Design;Jun2008, Vol. 14 Issue 17, p1686 

    The goal of treatment for acute hepatitis C patients is to eradicate the virus in the early phase of infection, thus preventing progression to chronicity. Early interferon (IFN) monotherapy has been shown to significantly reduce this risk, and therefore it has been recommended by international...

  • Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. Osinusi, Anuoluwapo; Meissner, Eric G.; Yu-Jin Lee; Bon, Dimitra; Heytens, Laura; Nelson, Amy; Sneller, Michael; Kohli, Anita; Barrett, Lisa; Proschan, Michael; Herrmann, Eva; Shivakumar, Bhavana; Wenjuan Gu; Kwan, Richard; Teferi, Geb; Talwani, Rohit; Silk, Rachel; Kotb, Colleen; Wroblewski, Susan; Fishbein, Dawn // JAMA: Journal of the American Medical Association;8/28/2013, Vol. 310 Issue 8, p804 

    IMPORTANCE The efficacy of directly acting antiviral agents in interferon-free regimens for the treatment of chronic hepatitis C infections needs to be evaluated in different populations. OBJECTIVE To determine the efficacy and safety of sofosbuvir with weight-based or low-dose ribavirin among a...

  • PEG INF-α-2a/ribavirin cost effective for mild-chronic hep C.  // PharmacoEconomics & Outcomes News;1/28/2006, Issue 495, p4 

    Discusses research being done on the use of Peginterferon-alpha-2a/ribavirin for treating mild-chronic hepatitis C. Reference to study being done by J. Hornberger et al, which appeared in the October 2006 issue of the journal "Hepatology"; Therapeutic use and mechanism of action of the drugs;...

  • Simeprevir.  // Australian Prescriber;Apr2015, Vol. 38 Issue 2, p67 

    The article offers information on the Simeprevir drug for the treatment of hepatitis C. It mentions its trial in treating patients suffering from genotype 1 infection as well as its effectiveness in people co-infected with HIV. It also presents a chart depicting its efficacy and addition to...

  • A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. Tahara, Hiroki; Takagi, Hitoshi; Sato, Ken; Shimada, Yasushi; Tojima, Hiroki; Hirokawa, Tomoyuki; Ohyama, Tatsuya; Horiuchi, Katsuhiko; Naganuma, Atsushi; Arai, Hirotaka; Kakizaki, Satoru; Mori, Masatomo // Journal of Gastroenterology;Aug2011, Vol. 46 Issue 8, p1010 

    Background: Although partial splenic embolization (PSE) is reportedly effective prior to interferon (IFN)-based therapy, the number of subjects in these studies is small, and the appropriate candidates and disease prognosis remain unknown. Methods: PSE was performed in 30 patients with advanced...

  • Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Oze, Tsugiko; Hiramatsu, Naoki; Yakushijin, Takayuki; Mochizuki, Kiyoshi; Oshita, Masahide; Hagiwara, Hideki; Mita, Eiji; Ito, Toshifumi; Inui, Yoshiaki; Fukui, Hiroyuki; Hijioka, Taizo; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Inoue, Atsuo; Imai, Yasuharu; Hayashi, Eijiro; Kato, Michio; Hosui, Atsushi; Miyagi, Takuya // Journal of Gastroenterology;Aug2011, Vol. 46 Issue 8, p1031 

    Background: It is still not known which patients with chronic hepatitis C who failed to respond to previous pegylated interferon (Peg-IFN) plus ribavirin therapy can benefit from re-treatment. Methods: Seventy-four patients (HCV genotype 1, n = 56, genotype 2, n = 18) were re-treated with...


Read the Article


Sign out of this library

Other Topics